Azenta (AZTA) Is Up 11.5% After Returning To Profit And Raising Revenue Outlook - Has The Bull Case Changed?
Azenta (AZTA) recently reported a return to profitability in Q3 2026, with net income of US$2.46 million and revenue of US$161.18 million, alongside a US$50 million share repurchase. The company also raised its full-year revenue guidance to US$613-US$618 million, signaling increased confidence in its operations. While these developments support the bull case for Azenta's long-term profitability in sample management and multiomics, the article cautions that ongoing pressures in certain services and elevated R&D spending could still impact margins and free cash flow.
Azenta (AZTA) Is Up 11.5% After Returning To Profit And Raising Revenue Outlook - Has The Bull Case Changed?
Azenta (AZTA) reported a strong third quarter in 2026, returning to profitability with US$2.46 million in net income and US$161.18 million in revenue, while also raising its full-year revenue guidance to US$613-US$618 million. The company completed a US$50 million share repurchase, which, combined with the return to positive earnings, suggests a more confident outlook for its operations and cash generation. While these updates are positive, the article notes that ongoing softness in certain business lines and high R&D spending could still impact future margins and free cash flow.
Weekly Recap: Azenta, Inc. Q3 revenue gain and analyst target raises
Azenta, Inc. (NASDAQ:AZTA) reported a strong Q3 with revenue up 12% year-over-year to $161.2M, driven by organic growth in Sample Management and Multiomics. The company announced a new buyback program, maintaining strong liquidity, and analysts subsequently raised price targets to $35 and $37 with buy/outperform ratings.
ETFs Investing in Azenta, Inc. Stocks
This article provides a list of ETFs that hold Azenta, Inc. stocks, detailing each fund's market value, weight of Azenta in its portfolio, issuer, management style, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The information aims to make investing in Azenta through ETFs more accessible by highlighting diversified options with potentially lower risk.
Securities Fraud Investigation Into Azenta, Inc. (AZTA) Continues
Glancy Prongay Wolke & Rotter LLP is continuing its securities fraud investigation into Azenta, Inc. (AZTA) on behalf of investors who lost money. The investigation follows Azenta's Q2 2026 financial results, which missed consensus estimates and led to a significant stock price drop after the company reduced its 2026 outlook and reported a goodwill impairment. Shareholders are urged to contact the firm to inquire about potentially pursuing claims.
Securities Fraud Investigation Into Azenta, Inc. (AZTA) Continues
Glancy Prongay Wolke & Rotter LLP is continuing its investigation into Azenta, Inc. (NASDAQ: AZTA) for potential violations of federal securities laws. This follows a significant drop in Azenta's stock price after the company reported disappointing Q2 2026 financial results, including missing EPS and revenue estimates, recording a $149 million goodwill impairment, and reducing its 2026 outlook. Shareholders who incurred losses are encouraged to contact the law firm to learn about potentially pursuing claims.
Azenta, Inc. $AZTA Stake Cut by Quantinno Capital Management LP
Quantinno Capital Management LP significantly reduced its stake in Azenta, Inc. (NASDAQ:AZTA) by 63.3% in the first quarter, selling over 391,000 shares and retaining 226,690 shares valued at approximately $4.79 million. Despite this, Azenta recently surpassed quarterly earnings expectations, reporting an adjusted EPS of $0.16 against a $0.11 consensus and revenue of $161.18 million. Analyst sentiment is mixed, with a consensus "Hold" rating and an average price target of $41.20, although Needham raised its target to $37.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Azenta, Inc. (AZTA) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Azenta, Inc. (NASDAQ: AZTA) on behalf of investors. This follows Azenta's Q2 2026 financial results, which missed consensus estimates for EPS and revenue, reported a $149 million goodwill impairment, and led to a reduced 2026 outlook. The firm encourages affected investors to contact them to assist with the investigation.
Arrowstreet Capital Limited Partnership Buys New Position in Azenta, Inc. $AZTA
Arrowstreet Capital Limited Partnership has acquired a new position in Azenta, Inc. (NASDAQ:AZTA), purchasing 71,410 shares valued at approximately $1.51 million, representing about 0.15% of the company. This comes as Azenta reported strong quarterly earnings, exceeding analyst estimates for both EPS and revenue, though it still maintains a negative net margin. Institutional investors hold a significant 99.08% stake in Azenta, and analyst sentiment is mixed but leaning positive, with Needham raising its price target to $37.
Azenta, Inc. 3Q 2026: Revenue $161.18M, EPS $0.05— 10-Q Summary
Azenta, Inc. reported strong third-quarter 2026 results, with revenue increasing 12% year-over-year to $161.18 million and diluted EPS reaching $0.05, a significant improvement from a loss in the prior year. The company returned to a net income of $2.46 million, driven by growth in its SMS and Multiomics segments and the acquisition of the UK Biocentre. Azenta also divested B Medical Systems to sharpen its strategic focus.
Azenta, Inc. Stock 12‑Month Price Target Raised to $33.8, Implies 12% Upside
Azenta, Inc.'s stock price target has been increased from $27.8 to $33.8 by five analysts, implying a 12% potential upside based on its August 4th closing price. The consensus rating for the stock remains a "Buy" from six analysts. Investors can find more detailed price target data and analyst recommendations on the Forecasts tab and News Flow sections of TradingView.
Azenta Q3 2026 EPS Tops Expectations, Revenue Up 12%
Azenta, Inc. reported strong Q3 2026 results, with Non-GAAP Diluted EPS of $0.16, significantly exceeding Wall Street's estimate of $0.12. The company's revenue rose 12.0% year-over-year to $161.2M, primarily driven by impressive organic growth of 9.0% and strong performance in its Sample Management Solutions segment. Despite the positive financial performance, Azenta's shares traded largely unchanged, possibly due to broader market concerns or investors awaiting clearer forward guidance.
Azenta, Inc. (AZTA) SVP acquires 335 shares via 2017 stock purchase plan
Ephraim Starr, SVP, General Counsel & Secretary of Azenta, Inc. (AZTA), purchased 335 shares of common stock on July 31, 2026, at $24.1676 per share through the company's 2017 Employee Stock Purchase Plan. This transaction, which was exempt from Section 16(b), increased his direct holdings to 68,728 shares. The filing was accepted by the SEC on August 4, 2026, and provides details of the insider trading activity.
Earnings Flash (AZTA) Azenta, Inc. Posts Q3 Adjusted EPS $0.16 per Share
Azenta, Inc. (AZTA) announced its Q3 adjusted EPS of $0.16 per share, surpassing FactSet's estimate of $0.11. The company also reported Q3 revenue of $161.2 million, exceeding FactSet's estimate of $149.3 million. This financial update indicates a stronger performance than anticipated by analysts for the quarter ended June 30, 2026.
Azenta reports Q3 fiscal 2026: Revenue $161M, Adjusted EBITDA $18.5M, Non-GAAP EPS $0.16
Azenta (AZTA) reported its fiscal Q3 2026 results with revenue of $161.2 million and non-GAAP diluted EPS of $0.16. The company achieved an adjusted EBITDA of $18.5 million, representing an 11.4% margin, and noted 9% organic revenue growth year over year. Azenta also reiterated its fiscal 2026 adjusted EBITDA guidance of $59–62 million.
Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026.
Azenta, Inc. reported its third-quarter financial results for fiscal year 2026, exceeding expectations with continued strength in recurring revenue and a modest improvement in Multiomics in North America. The company's revenue from continuing operations was $161 million, an increase of 12% year-over-year, and it issued updated guidance for both the fourth quarter and full fiscal year 2026. This report also included details on the sale of its B Medical Systems business, which was completed on July 1, 2026.
Azenta earnings on deck: Can life sciences firm return to profit?
Azenta Inc. is scheduled to report its fiscal third-quarter earnings, with analysts expecting a return to profitability at $0.10 per share on $149.29 million in revenue, a significant improvement from the previous quarter's loss. Investors will be closely watching for sustained profitability, North American demand trends, and improvements in margins following management's acknowledgment of prior execution gaps and a cautious market. The company has taken steps to streamline its portfolio and introduce new products, and upcoming results will be crucial for validating its recovery efforts.
Earnings Flash (AZTA) Azenta, Inc. Reports Q3 Revenue $161.2M, vs. FactSet Est of $149.3M
Azenta, Inc. (AZTA) reported its Q3 revenue at $161.2 million, surpassing FactSet's estimate of $149.3 million. This financial news highlights a stronger-than-anticipated performance for the biotechnology and medical research company in its third fiscal quarter. The report also mentions other recent financial updates for Azenta, including its Q3 adjusted EPS and revised earnings guidance.
Earnings Flash (AZTA) Azenta, Inc. Posts Q3 Adjusted EPS $0.16 per Share, Vs. FactSet Est of $0.11
Azenta, Inc. (AZTA) announced its Q3 adjusted EPS of $0.16 per share, surpassing the FactSet estimate of $0.11 per share. This indicates a stronger financial performance than anticipated by analysts.
Azenta (AZTA) Reports Q2: Everything You Need To Know Ahead Of Earnings
Azenta (AZTA) is set to report its Q2 earnings this Tuesday. The company missed revenue and EPS expectations last quarter, but analysts expect a 3.7% year-on-year revenue growth for the upcoming quarter, reversing a previous decline. Investors are keen to see if Azenta, currently trading near its average analyst price target, can deliver a positive surprise.
Azenta (AZTA) Reports Q2: Everything You Need To Know Ahead Of Earnings
Azenta (NASDAQ: AZTA), a life sciences company, is set to report its Q2 earnings this Tuesday. The company missed revenue expectations last quarter, reporting $144.8 million, and analysts are now forecasting a 3.7% year-over-year revenue growth. Investors will be watching closely to see if Azenta can meet or exceed these expectations, especially given its history of missing Wall Street's revenue estimates.
Azenta Inc (AZTA) Financial Health: Profitability & Balance Sheet Analysis
Azenta Inc (AZTA) currently holds a financial score of 8.14, placing it in the top 60 of 384 companies in the Biotechnology & Medical Research industry, indicating robust financial health and high operating efficiency. The company recently reported a quarterly revenue of $144.79 million, marking a 0.96% year-over-year increase, and a significant 297.46% year-over-year rise in net profit. However, specific detailed data for various financial components like cash flow, assets, and liabilities have not yet been disclosed by the company.
Azenta Inc (AZTA) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Azenta Inc (AZTA), focusing on its P/E ratio and overall valuation score. Azenta's current valuation score is 8.18, placing it 160th out of 384 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is currently -7.51, which is significantly below its recent high and above its recent low.
Azenta Number of Employees 2026 | Employee Count & Headcount Data
Azenta, Inc. (AZTA) had approximately 3,042 total employees worldwide as of March 2026, representing a 6.4% decline from 2023. The company is actively hiring, though job postings decreased by 31.6% in 2026 compared to 2025. The workforce is primarily concentrated in the United States, and the average employee salary globally is $71,563.
Azenta Inc (AZTA) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Azenta Inc (AZTA), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. While the stock currently trades between a resistance level of $30.57 and a support level of $25.77, suggesting suitability for range-bound swing trading, the overall signal from technical indicators is Neutral, though moving averages show strong buy signals. The analysis also includes FAQs explaining technical ratings and moving averages.
AZTA|Azenta Inc|Price:27.520|Chg%:+0.150
Azenta Inc. (AZTA) is a provider of life sciences solutions, specializing in cold-chain sample management and multiomics services for drug development, clinical research, and advanced cell therapies. The article details the company's business segments, key brands, financial data, and lists its executive team and prominent shareholders. As of the latest update, its stock trades at $27.520, reflecting a 0.55% increase.
Azenta Inc (AZTA) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Azenta Inc (AZTA), detailing its current earnings forecast score, average price target, and analyst ratings. It indicates that the company's expected revenue for the next quarter is $149.29 million, with analysts largely recommending a "Buy" for the stock.
Azenta, Inc. Revenue Breakdown – NASDAQ:AZTA
Azenta, Inc. (NASDAQ: AZTA) generated $593.82 million in revenue last year. The Sample Management Solutions segment was the top performer, contributing $324.59 million. The United States was the greatest regional contributor, accounting for $365.00 million.
Brooks Automation Weighs IPO Amid Surge in PE-Backed Listings
Brooks Automation, a company specializing in robotics and automation software for semiconductor, life sciences, and industrial manufacturing, is considering an initial public offering. This move comes as the U.S. IPO market experiences a significant surge, particularly with private equity-backed listings. The company, owned by Thomas H. Lee Partners, aims to capitalize on the favorable market conditions, following a trend of other PE-backed firms going public to cash out investments.
Azenta, Inc. Revenue Breakdown – LSE:0HQ1
Azenta, Inc. (LSE:0HQ1) generated a total revenue of $593.82 million USD last year. The Sample Management Solutions segment was the top-performing segment, contributing $324.59 million USD, while the United States was the largest regional contributor with $365.00 million USD in revenue.
Robotics firm Brooks Automation weighs IPO - Bloomberg By Investing.com
Brooks Automation, a robotics and software automation company, is reportedly considering an initial public offering. The company, backed by Thomas H. Lee Partners, was formed after a $3 billion carve-out from the former Brooks Automation, with its life sciences arm renamed Azenta Inc. Deliberations are ongoing for the Chelmsford, Massachusetts-based firm, which specializes in automation for semiconductor manufacturing and life sciences.
Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast
Azenta, Inc. (NASDAQ: AZTA) will host a conference call and webcast on August 6, 2026, to discuss its financial results for the third quarter of fiscal year 2026. The company intends to issue a press release detailing these results after the market closes on August 5, 2026. Investors can access the live webcast or a replay through the company's investor relations website.
Azenta to announce fiscal Q3 2026 earnings on Aug 4
Azenta, Inc. will announce its fiscal third-quarter 2026 financial results after market close on August 4, 2026, for the period ending June 30, 2026. A conference call and live webcast will follow on August 5, 2026, at 8:30 a.m. Eastern Time to discuss these results. Azenta provides life sciences solutions globally, including cold-chain sample management and multiomics services.
Azenta to report quarter ended June 30 after market close
Azenta (Nasdaq: AZTA) will release its fiscal third-quarter 2026 earnings, covering the period ended June 30, 2026, on Tuesday, August 4, 2026, after the market close. A conference call and live webcast to discuss the results will be held on Wednesday, August 5, 2026, at 8:30 a.m. Eastern Time, with replay available from August 6, 2026. Interested parties can access the webcast via the company's investor relations website.
Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast
Azenta, Inc. (Nasdaq: AZTA) will release its fiscal third quarter 2026 earnings on Tuesday, August 4, 2026, after market close. The company will then host a conference call and live webcast on Wednesday, August 5, 2026, at 8:30 a.m. Eastern Time to discuss these financial results. Investors and media can access the webcast and a replay via the Azenta website.
Azenta (AZTA) Q1 2025 earnings summary
Azenta (AZTA) reported a 4% year-over-year revenue increase in Q1 2025 to $148 million, driven by growth in both Sample Management Solutions and Multiomics segments. The adjusted EBITDA margin expanded to 9.0%, and non-GAAP EPS was $0.08. The company is actively selling B Medical Systems and ended the quarter with $530 million in cash and no debt, while reiterating full-year 2025 guidance for organic revenue growth and EBITDA margin expansion.
Azenta (AZTA) AGM 2026 Summary
Azenta's (AZTA) 2026 AGM highlighted a transformative year, disciplined strategy, and margin expansion, with $546 million in cash for strategic investments. The leadership stability was affirmed by the presence of most board members and the CEO. Financial performance showed meaningful growth in core businesses despite macroeconomic challenges.
Azenta (AZTA) M&A announcement Summary
Azenta (AZTA) announced the acquisition of UK Biocentre for GBP 20.5 million, funded by cash on hand. This strategic move expands Azenta's European presence, particularly in the UK, and strengthens its life sciences biorepository operations. The acquisition is expected to be dilutive to Adjusted EBITDA margin in 2026 but accretive to revenue growth and margin expansion in 2027 and 2028, driven by operational and revenue synergies.
Azenta (AZTA) Investor Day 2025 Summary
Azenta's (AZTA) Investor Day 2025 outlined a strategic shift to a decentralized operating model, emphasizing operational excellence through the Azenta Business System and disciplined capital allocation, including a $250 million share repurchase program. The company plans significant growth initiatives, such as scaling biorepositories to 100 million samples by 2030 and regionalizing gene synthesis, targeting substantial addressable markets in SRS/SMS and Multiomics. Key to their strategy are investments in automation, digital transformation, and enhancing recurring revenue streams, supported by a strong go-to-market approach and experienced leadership.
BA3 Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Azenta, Inc. (BA3) stock, based on analyst opinions. It highlights the company's financial performance, including past earnings and revenue, and projected future earnings. Additionally, it offers information on the stock's highest and lowest prices ever, upcoming earnings dates, and how to buy its shares.
Azenta (AZTA) Q2 2026 earnings summary
Azenta (AZTA) reported Q2 2026 revenue of $145 million, a 1% year-over-year increase, but organic revenue declined by 3% due to weakness in Multiomics and Sample Management Solutions. The company incurred a net loss of $160.8 million, driven by a $149 million goodwill impairment charge, and adjusted EBITDA margin fell to 5.4%. Azenta has extended its long-range plan to 2029 and completed the acquisition of UK Biocentre.
Azenta (AZTA) Q1 2026 earnings summary
Azenta (AZTA) reported Q1 2026 revenue of $149 million, a 1% year-over-year increase, though organic revenue declined by 1%. The company achieved $15 million in free cash flow and maintained a strong cash position with $571 million in cash and equivalents. Azenta reaffirmed its fiscal 2026 guidance, targeting 3%-5% organic revenue growth and approximately 300 basis points adjusted EBITDA margin expansion, with acceleration expected in the second half of the fiscal year.
AZTA Earning Date, Earning Analysis and Earning Prediction
The article provides an earning analysis and prediction for AZTA, highlighting past quarterly results and future forecasts. Analysts project 2026/Q3 revenue of $155.09M and an EPS of $0.22, with revenue and EPS estimates unchanged over the past three months, correlating with a 6.95% stock price change. The report also details historical stock reactions to earnings announcements and addresses frequently asked questions about AZTA's performance and outlook.
Azenta (Nasdaq: AZTA) closes $63M sale of B Medical unit with vendor loan
Azenta (Nasdaq: AZTA) has completed the sale of its B Medical Systems business to Thelema S.à r.l. for $63 million. The consideration included $28 million in cash and a $35 million short-term secured vendor loan to Thelema, structured as a related-party transaction due to Thelema being majority-owned by B Medical’s CEO. The sale aligns with Azenta's strategy to focus on core life sciences businesses and provides enhanced financial flexibility.
Azenta announces completion of B Medical Systems sale to Thelema S.a r.l; Whitestone Group acquires a 40% Stake in Thelema S.a r.l, a Special Purpose Vehicle (SPV) established for the ownership of B Medical Systems
Azenta, Inc. has finalized the sale of B Medical Systems S.á r.l (BMS) to Thelema S.a r.l for $63 million in cash. As part of this transaction, Whitestone Group acquired a 40% stake in BMS through Thelema S.a r.l, investing $19 million. The acquisition aligns with Whitestone Group's investment strategy in European industrial companies and marks a new chapter for BMS under CEO Luc Provost's leadership, focusing on diversification and compliance with global health standards.
Azenta completes sale of B Medical Systems for $63 million By Investing.com
Azenta Inc. has completed the sale of its B Medical Systems business to Thelema S.à r.l. for $63 million in cash, a move aimed at focusing on its core life sciences operations. Despite recent disappointing financial results for Q2 2026, analysts predict a return to profitability for Azenta this year, with InvestingPro suggesting the stock is currently undervalued. The company maintains a strong balance sheet and has provided a short-term vendor loan to Thelema as part of the transaction.
Azenta completes $63 million B Medical Systems sale
Azenta (NASDAQ:AZTA) has completed the sale of its B Medical Systems business to Thelema S.à r.l. for $63 million. This transaction, which included a $35 million vendor loan from Azenta, aligns with Azenta's strategy to streamline its portfolio and concentrate on its core life sciences operations. B Medical Systems specializes in temperature-controlled storage solutions for healthcare and life sciences.
Azenta completes sale of B Medical Systems for $63 million
Azenta Inc. has completed the sale of its B Medical Systems business to Thelema S.à r.l. for $63 million in cash, furthering its strategy to focus on core life sciences businesses. The transaction closed on July 1, 2026, and Azenta provided a short-term vendor loan of $35 million to finance part of the purchase. Despite recent disappointing financial results, analysts predict Azenta will return to profitability, with the stock currently considered undervalued.
Press Release: Azenta Completes Sale of B Medical Systems
Azenta, Inc. (Nasdaq: AZTA) has announced the completion of the sale of its Brooks Life Sciences (BLS) consumable products and instruments business, B Medical Systems S.à r.l. and its subsidiaries, to B Medical Systems, S.a.r.l. for approximately €145 million in cash. This strategic divestiture follows Azenta's broader strategy to streamline its portfolio and focus on its core life sciences tools and services. The proceeds from the sale are expected to support Azenta's ongoing growth initiatives and capital allocation strategies.
Azenta Finalizes B Medical Divestiture With $35 Million Vendor Loan and Share Pledge
Azenta has finalized the sale of B Medical to Thelema, involving a $35 million vendor loan from Azenta to the buyer. This loan carries 6% interest, a three-month maturity, and is secured by a first-priority pledge over 100% of B Medical's equity. This arrangement facilitates the closing of the transaction and is considered part of the total $63 million purchase price.
